4
Changes in Ownership
Mineralys Therapeutics, Inc. Filed Acc 0001933414-25-000151
Chief Executive Officer sold 200,000 shares at an average $45.44 ($9,088,499)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −12,806 | $41.64 | $533,235 | 818,499 | D |
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −8,862 | $42.31 | $374,947 | 809,637 | D |
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −4,000 | $43.50 | $173,984 | 805,637 | D |
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −29,207 | $45.20 | $1,320,165 | 776,430 | D |
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −112,275 | $45.83 | $5,145,956 | 664,155 | D |
| Congleton Jon Chief Executive Officer | 2025-11-11 | Sale | −32,850 | $46.89 | $1,540,212 | 631,305 | D |
| Open-market sales · 200,000 sh · avg $45.44 · $9,088,499 | |||||||
Loading xslF345X05/wk-form4_1763078487.xml…